Using a unique new technique, US researchers hope to offer a safer and more effective alternative to current cancer treatments, reporting promising first results in mice.
A new molecular test for bacteria and viruses, including Sars-CoV-2, has been developed at the University of Surrey, as they warn that the world needs to be prepared for the next pandemic.
Researchers at Harvard Medical School developed a new tool that promises to improve the way pathologists see and evaluate a tumor by providing detailed clues about the cancer.
Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease.
The Pluslife Mini Dock System is a Next-Generation POC molecular diagnostic tool that can be used in different application scenarios, which aims to help the decentralization of MDx in diagnosing facilities.
The coronavirus pandemic is a huge challenge for global public health and welfare. Decentralized, affordable POC MDx platforms would allow more effective control of SARS-CoV-2 and other infections.
As more genomic alterations become targets for therapy, health institutions and hospitals are creating specialist Molecular Tumour Boards to support better decision-making for patient care. This evolving team, and its role, was highlighted in a presentation at the 34th European Congress of Pathology in Basel, Switzerland.
A considerable proportion of patients suffering from cancer of unknown primary (CUP) could benefit from comprehensive molecular analysis and molecularly-informed targeted therapies.
A new AI platform can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process.
With micro-organisms and viruses constantly developing, mutating, and evolving, diagnostics must adapt just as rapidly. Advanced laboratory technology and instruments are undeniably a prerequisite for best practice in life sciences and biotechnology.
One size does not fit all when it comes to diagnostics. Different diagnostic locations need solutions that meet their needs, whether for on-demand testing in a healthcare setting or a laboratory managing population screening. Finding the right solution can be a challenge especially when the future may change what a laboratory needs, Hologic Inc. reports.
A new rapid molecular diagnostic test from Cepheid has received the CE mark for distribution in the European market. The test, called Xpert Xpress CoV-2/Flu/RSV plus, is designed for qualitative detection of the viruses causing Covid-19, Flu A, Flu B, and respiratory syncytial virus (RSV) infections from a single patient sample. The new plus version of the test provides a third gene target for…
Antibiotic resistant bacteria are a looming super threat – heralding a time when our drugs will no longer be effective against prevalent infections. Hospitals are already coping with treatment-resistant bacterial infections. Cognizant of the threat and thinking outside the box, BGU scientists and German and American colleagues have developed a pair of 'molecular tweezers' to destroy the biofilm…
Intrahepatic cholangiocarcinoma (ICC) develops within the liver. With one to two cases per 100,000 inhabitants in Germany, ICC is one of the rare diseases overall, but it is the second most common liver cancer. The aggressive bile duct tumour remains clinically inconspicuous for a long time, so that it is often only detected late. Because the tumour also only responds to chemotherapy to a limited…
Using a nanopore, researchers have demonstrated the potential to reduce the time required for sequencing a glycosaminoglycan — a class of long chain-linked sugar molecules as important to our biology as DNA — from years to minutes. Research to be published this week in the Proceedings of the National Academies of Sciences shows that machine-learning and image recognition software could be…
Hologic, Inc. has announced that it will acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments.
University of Maryland scientists have developed a method to determine the structures of large RNA molecules at high resolution.
If chromosomes are unevenly distributed or otherwise altered during cell division, this normally damages the daughter cells and impairs their viability. Not in cancer cells, however, in which chromosome instability can actually confer a growth advantage under certain circumstances. Moreover, as scientists from the German Cancer Research Center have now demonstrated in mice, changes in the…
Scientists have created one of the most detailed maps of breast cancer ever achieved, revealing how genetic changes shape the physical tumour landscape. An international team of scientists, brought together by a £20 million Grand Challenge award from Cancer Research UK, has developed intricate maps of breast tumour samples, with a resolution smaller than a single cell. These maps show how the…
